Literature DB >> 16529936

Synthesis and biological evaluation of (3,4,5-trimethoxyphenyl)indol-3-ylmethane derivatives as potential antivascular agents.

Grégory Dupeyre1, Guy G Chabot, Sylviane Thoret, Xavier Cachet, Johanne Seguin, Daniel Guénard, François Tillequin, Daniel Scherman, Michel Koch, Sylvie Michel.   

Abstract

Combretastatin A-4 (CSA-4), a stilbene derivative, is a potent vascular disrupting agent (VDA) with the structural requirement of a cis-configuration to maintain a molecular geometry and a correct orientation of both phenyl groups. A series of indolic analogues of CSA-4 was synthesized by means of an efficient strategy. Six compounds (20b, 25b-27b, 32b, and 35b) were identified as potent inhibitors of tubulin polymerization and also displayed cytotoxic activities on B16 melanoma cells at a nanomolar level. Both activities were well correlated with the ability to induce morphological changes of EA.hy 926 endothelial cells. In conclusion, the cis-stilbene skeleton of CSA-4 could conveniently be replaced by the 3-aroylindolic moiety, thus avoiding any isomerization leading to inactive trans compounds.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16529936     DOI: 10.1016/j.bmc.2006.02.037

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  7 in total

1.  Design, synthesis and structure-activity relationship of 2-(3',4',5'-trimethoxybenzoyl)-benzo[b]furan derivatives as a novel class of inhibitors of tubulin polymerization.

Authors:  Romeo Romagnoli; Pier Giovanni Baraldi; Maria Dora Carrion; Carlota Lopez Cara; Olga Cruz-Lopez; Manlio Tolomeo; Stefania Grimaudo; Antonietta Di Cristina; Maria Rosaria Pipitone; Jan Balzarini; Nicola Zonta; Andrea Brancale; Ernest Hamel
Journal:  Bioorg Med Chem       Date:  2009-08-20       Impact factor: 3.641

2.  Synthesis and evaluation of indole-based chalcones as inducers of methuosis, a novel type of nonapoptotic cell death.

Authors:  Michael W Robinson; Jean H Overmeyer; Ashley M Young; Paul W Erhardt; William A Maltese
Journal:  J Med Chem       Date:  2012-02-28       Impact factor: 7.446

3.  New arylthioindoles and related bioisosteres at the sulfur bridging group. 4. Synthesis, tubulin polymerization, cell growth inhibition, and molecular modeling studies.

Authors:  Giuseppe La Regina; Taradas Sarkar; Ruoli Bai; Michael C Edler; Roberto Saletti; Antonio Coluccia; Francesco Piscitelli; Lara Minelli; Valerio Gatti; Carmela Mazzoccoli; Vanessa Palermo; Cristina Mazzoni; Claudio Falcone; Anna Ivana Scovassi; Vincenzo Giansanti; Pietro Campiglia; Amalia Porta; Bruno Maresca; Ernest Hamel; Andrea Brancale; Ettore Novellino; Romano Silvestri
Journal:  J Med Chem       Date:  2009-12-10       Impact factor: 7.446

4.  Synthesis and biological evaluation of isomeric methoxy substitutions on anti-cancer indolyl-pyridinyl-propenones: Effects on potency and mode of activity.

Authors:  Christopher J Trabbic; Sage M George; Evan M Alexander; Shengnan Du; Jennifer M Offenbacher; Emily J Crissman; Jean H Overmeyer; William A Maltese; Paul W Erhardt
Journal:  Eur J Med Chem       Date:  2016-06-13       Impact factor: 6.514

5.  Flavonoid-induced morphological modifications of endothelial cells through microtubule stabilization.

Authors:  Yasmine S Touil; Arlette Fellous; Daniel Scherman; Guy G Chabot
Journal:  Nutr Cancer       Date:  2009       Impact factor: 2.900

6.  Nanoliposomes for encapsulation and delivery of the potential antitumoral methyl 6-methoxy-3-(4-methoxyphenyl)-1H-indole-2-carboxylate.

Authors:  Ana S Abreu; Elisabete Ms Castanheira; Maria-João Rp Queiroz; Paula Mt Ferreira; Luís A Vale-Silva; Eugénia Pinto
Journal:  Nanoscale Res Lett       Date:  2011-08-03       Impact factor: 4.703

7.  Design, Synthesis and Cytotoxicity Evaluationof New 1,2-diaryl-4, 5, 6, 7-Tetrahydro-1H-benzo[d] Imidazolesas Tubulin Inhibitors.

Authors:  Marzieh Amirmostofian; Farzad Kobarfard; Hamed Reihanfard; Vida Mashayekhi; Afshin Zarghi
Journal:  Iran J Pharm Res       Date:  2015       Impact factor: 1.696

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.